Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4, has revolutionized lung cancer treatment.
• However, a significant proportion of patients (30-50%) exhibit primary or acquired resistance to ICIs, limiting long-term benefits.

Purpose of the Study:

• To review the complex immune mechanisms underlying resistance to immune checkpoint inhibitors in lung cancer.
• To explore diverse combination strategies aimed at overcoming ICI resistance.
• To discuss predictive biomarkers for identifying patient populations likely to benefit from ICI therapy and combination treatments.

Main Methods:

• Comprehensive literature review of studies on lung cancer immunotherapy resistance.
• Analysis of molecular and cellular mechanisms contributing to primary and acquired resistance.
• Evaluation of preclinical and clinical data on combination therapies involving ICIs.
• Assessment of current and emerging biomarkers for predicting ICI response.

Main Results:

• Resistance to ICIs is multifactorial, involving issues in antigen presentation, gene mutations, and the tumor microenvironment.
• Various combination strategies, including chemotherapy, targeted therapy, and other immunotherapies, show promise in enhancing ICI efficacy.
• Biomarker research is crucial for stratifying patients and predicting response to different treatment approaches.

Conclusions:

• Understanding ICI resistance mechanisms is key to developing more effective lung cancer treatments.
• Combination therapies and biomarker-driven patient selection are essential for maximizing the benefits of immunotherapy.
• Future research should focus on personalized medicine approaches to overcome resistance and improve survival rates in lung cancer patients.